Eight reasons for using telmisartan Review article
Article Sidebar
Published:
Sep 30, 2014
Keywords:
hypertension, sartans, angiotensin II receptor blockers
Main Article Content
Abstract
According to the current guidelines of the European Society of Cardiology on the management of patients with hypertension we have available five basic classes of antihypertensive drugs: angiotensin converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, diuretics and beta blockers. In each of these groups, although with a similar mechanism of action, we can find drugs with their specific properties. In case of antagonists of angiotensin receptors, molecule that is very interesting – telmisartan is characterized by long life, stable 24 hours reduction of blood pressure and the possibility of the use in hypertensive patients with increased cardiovascular risk.
Article Details
How to Cite
Balsam , P. (2014). Eight reasons for using telmisartan. Medycyna Faktow (J EBM), 7(3(24), 35-39. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2351
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Charakterystyka Produktu Leczniczego – Telmisartan.
2. Charakterystyka Produktu Leczniczego – Ramipril.
3. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood pressure Supplement 2001; 1: 27-32.
4. Petrovic I., Petrovic D., Vukovic N. et al.: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J. Int. Med. Res. 2005; 33(Suppl. 1): 39A-49A.
5. Galzerano D., Tammaro P., del Viscovo L. et al.: Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am. J. Hypertens. 2005; 18(12 Pt 1): 1563-9.
6. Barnett A.H., Bain S.C., Bouter P. et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351(19): 1952-61.
7. Muller J.E., Stone P.H., Turi Z.G. et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. 1985; 313(21): 1315-22.
8. Amodeo C., Guimaraes G.G., Picotti J.C. et al.: Morning blood pressure surge is associated with death in hypertensive patients. Blood pressure monitoring 2014; 19(4): 199-202.
9. Zannad F., Matzinger A., Larche J.: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypert. 1996; 9(7): 633-43.
10. Benson S.C., Pershadsingh H.A., Ho C.I. et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43(5): 993-1002.
11. Amano Y., Yamaguchi T., Ohno K. et al.: Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens. Res. 2012; 35(7): 715-9.
12. Miura Y., Yamamoto N., Tsunekawa S. et al.: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28(3): 757-8.
13. Bloom B.S.: Continuation of initial antihypertensive medication after 1 year of therapy. Clin. Ther. 1998; 20(4): 671-81.
14. Conlin P.R., Gerth W.C., Fox J. et al.: Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin. Ther. 2001; 23(12): 1999-2010.
15. Investigators O., Yusuf S., Teo K.K. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547-59.
16. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypert. 2013; 31(10): 1925-38.
17. Neldam S., Schumacher H., Kjeldsen S.E. et al.: Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. Curr. Med. Res. Opin. 2014 Jun 13: 1-10 [Epub ahead of print].
18. Segura J., Ruilope L.M.: A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc. Health Risk Manag. 2013; 9: 521-8.
19. Zhu D., Bays H., Gao P., Mattheus M. et al.: Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial. Integr. Blood Press. Control 2013; 6: 1-14.
20. Neldam S., Schumacher H., Guthrie R.: Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures. Adv. Ther. 2012; 29(4): 327-38.
21. Bays H., Gao P., Volker B. et al.: Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. Int. J. Hypert. 2013; 2013: 749830 [doi: 10.1155/2013/749830]. [Epub 2013 Apr 4].
2. Charakterystyka Produktu Leczniczego – Ramipril.
3. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood pressure Supplement 2001; 1: 27-32.
4. Petrovic I., Petrovic D., Vukovic N. et al.: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J. Int. Med. Res. 2005; 33(Suppl. 1): 39A-49A.
5. Galzerano D., Tammaro P., del Viscovo L. et al.: Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am. J. Hypertens. 2005; 18(12 Pt 1): 1563-9.
6. Barnett A.H., Bain S.C., Bouter P. et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351(19): 1952-61.
7. Muller J.E., Stone P.H., Turi Z.G. et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. 1985; 313(21): 1315-22.
8. Amodeo C., Guimaraes G.G., Picotti J.C. et al.: Morning blood pressure surge is associated with death in hypertensive patients. Blood pressure monitoring 2014; 19(4): 199-202.
9. Zannad F., Matzinger A., Larche J.: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypert. 1996; 9(7): 633-43.
10. Benson S.C., Pershadsingh H.A., Ho C.I. et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43(5): 993-1002.
11. Amano Y., Yamaguchi T., Ohno K. et al.: Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens. Res. 2012; 35(7): 715-9.
12. Miura Y., Yamamoto N., Tsunekawa S. et al.: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28(3): 757-8.
13. Bloom B.S.: Continuation of initial antihypertensive medication after 1 year of therapy. Clin. Ther. 1998; 20(4): 671-81.
14. Conlin P.R., Gerth W.C., Fox J. et al.: Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin. Ther. 2001; 23(12): 1999-2010.
15. Investigators O., Yusuf S., Teo K.K. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547-59.
16. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypert. 2013; 31(10): 1925-38.
17. Neldam S., Schumacher H., Kjeldsen S.E. et al.: Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension. Curr. Med. Res. Opin. 2014 Jun 13: 1-10 [Epub ahead of print].
18. Segura J., Ruilope L.M.: A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc. Health Risk Manag. 2013; 9: 521-8.
19. Zhu D., Bays H., Gao P., Mattheus M. et al.: Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial. Integr. Blood Press. Control 2013; 6: 1-14.
20. Neldam S., Schumacher H., Guthrie R.: Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures. Adv. Ther. 2012; 29(4): 327-38.
21. Bays H., Gao P., Volker B. et al.: Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. Int. J. Hypert. 2013; 2013: 749830 [doi: 10.1155/2013/749830]. [Epub 2013 Apr 4].